The immunoassay segment accounts about 35% of the market, with no growth compared to the previous year. Domestic brands account for over 35%.

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

Roche has won a nod from FDA for a new diagnostic for individual blood donation testing. The Basel-Switzerland-based company’s cobas Babesia test is for use on the cobas 6800 8800 system.

Razor Genomics has developed a test enables the identification of lung cancer patients at high risk for recurrence and allows them to be treated at a time when their cancer can still be responsive to adjuvant chemotherapy.

There’s a new entrant in the liquid biopsy space. Well, sort of. Even though OncoCell MDx was formed in 2012, it hasn’t made a great deal of noise up until this year.

Today’s molecular diagnostics testing typically involves either manual processing at a reference laboratory or automated processing by preconfigured instruments in near-patient settings, Dr. Jack Regan, CEO and founder of LexaGene, said. N

A new study from the University of South Australia researchers found the number of people that die from bowel or colorectal cancer (CRC) would be much higher without pre-diagnostic colonoscopies. Now more than 700,000 people die from bowel c

Two powerhouses in pharma and medtech are working together to help people with diabetes better manage their condition. Abbott Laboratories and Sanofi will collaborate to integrate glucose sensing and insulin delivery technologies.

A Danish and Taiwanese company has won Australia’s Good Design Award for a portable diagnostic device—small enough to fit in a camera case—that allows diagnosis of infectious diseases on the spot from a single drop of blood.

Looking east to the Pacific, there is Los Angeles, known as the "City of Angels." On the evening of 7 August, at the 71st American Association for Clinical Chemistry (AACC) in Los Angeles, the North American Chinese Clinical Chemists Associa

Quidel reported after the close of the market Thursday that its second quarter revenues rose 5 percent year over year due primarily to growth in the firm's rapid immunoassay business. Growth in molecular and specialized diagnostic solutions

Bio-Rad Laboratories reported after the close of the market Thursday that its second quarter revenues decreased approximately 1 percent year over year.